Durvalumab + Tremelimumab (STRIDE)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-TREMELIMUMAB` `DRUG-DURVALUMAB`

ID	`REG-DURVA-TREME-STRIDE`
Type	Regimen
Status	reviewed 2026-04-26 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-NCCN-HCC-2025`

Notes

HIMALAYA: STRIDE regimen 1L unresectable HCC, Child-Pugh A. mOS 16.4 vs 13.8 sorafenib. Preferred when bevacizumab contraindicated (varices, recent thromboembolic, severe HTN). Single priming-dose tremelimumab has acceptable safety vs older Q4W schedules. CTLA-4 irAE pattern earlier + more colitis vs PD-1 alone.

Used By

Indication

IND-HCC-SYSTEMIC-1L-DURVA-TREME - IND-HCC-SYSTEMIC-1L-DURVA-TREME